Arcus Biosciences to Present New Data from Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual Meeting
-
Updated data from EDGE-Gastric evaluating domvanalimab plus zimberelimab and chemotherapy in upper gastrointestinal (GI) cancers will be presented in a special ASCO plenary series rapid abstract update session by
Yelena Y. Janjigian , M.D., Chief Gastrointestinal Oncology,Memorial Sloan Kettering Cancer Center , and Lead Investigator for the EDGE-Gastric study
-
Data from ARC-9 evaluating an etrumadenant plus zimberelimab-based treatment combination in third-line metastatic colorectal cancer will be presented in an oral presentation by
Zev A. Wainberg , M.D., MSc, Co-Director UCLA Gastrointestinal Oncology Program, and Lead Investigator for the ARC-9 study
- Trial in Progress (TIP) poster for VELOCITY-Lung Substudy-03, a Phase 2 study of perioperative domvanalimab plus zimberelimab and chemotherapy in patients with resectable Stage II-III non-small cell lung cancer
“We will have two oral presentations for Phase 2 studies that highlight the potential for novel immuno-oncology mechanisms and combinations in gastrointestinal cancers,” said
Three Accepted Abstracts Will Be Presented
Study |
Title |
Abstract Number |
Session Type &
|
Session Date
|
Domvanalimab (Fc-silent anti-TIGIT monoclonal antibody) plus Zimberelimab (anti-PD-1 antibody) |
||||
EDGE-Gastric |
Updates on Abstract 433248: EDGE-Gastric Arm A1: Phase 2 study of domvanalimab, zimberelimab, and FOLFOX in first-line (1L) advanced gastroesophageal cancer. |
433248 |
ASCO Plenary Series: Rapid Abstract Updates |
6/01/2024,
|
VELOCITY-Lung Substudy-03 TIP |
VELOCITY-Lung substudy-03: A phase 2 study of neoadjuvant domvanalimab (dom)+zimberelimab (zim)+chemotherapy (chemo) or zim+chemo followed by adjuvant dom+zim or zim in patients with resectable stage II-III non-small cell lung cancer (NSCLC). |
TPS8121 |
Poster Session – Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers |
6/3/2024,
|
Etrumadenant (A2a/A2b receptor antagonist) |
||||
ARC-9 |
ARC-9: A Randomized Study to Evaluate Etrumadenant-Based Treatment Combinations in Previously Treated Metastatic Colorectal Cancer (mCRC) |
3508 |
Gastrointestinal Cancer—Colorectal and Anal: Oral Abstract Session |
6/2/2024,
|
About
Domvanalimab, zimberelimab and etrumadenant are investigational molecules. Neither Gilead nor Arcus has received approval from any regulatory authority for any use of these molecules, and their safety and efficacy for the treatment of gastrointestinal and lung cancers have not been established.
The Arcus name and logo are trademarks of
View source version on businesswire.com: https://www.businesswire.com/news/home/20240424647945/en/
Investor Inquiries:
VP of Investor Relations & Strategy
(617) 459-2006
peaves@arcusbio.com
Media Inquiries:
VP of Corporate Communications
(650) 922-1269
hkolkey@arcusbio.com
Source: